A great start to 2022 with yet another paper !!

Porsolt continues to play a significant role in research collaborations as demonstrated with the following paper just published by #Sunovion in the journal “Drug and Alcohol Dependence”.

Preclinical drug abuse and liability studies “suggest that the TAAR1/5-HT1A agonist ulotaront is not likely to pose a risk for recreational abuse in humans and may have potential therapeutic utility as a treatment of substance use disorders”.

To read the paper: https://lnkd.in/gz5gSe5V